Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Teske E, Naan EC, van Dijk EM, Van Garderen, Schalken JA. Canine prostate carcinoma: epidemiological evidence of an increased risk in castrated dogs. Mol Cell Endocrinol. 2002;197(1–2):251–255.
-
2.
Freitag T, Jerram RM, Walker AM, Warman CGA. Surgical management of common canine prostatic conditions. Com-pend Contin Educ Vet. 2007;29(11):656–658, 660.
-
3.
Cornell KK, Bostwick DG, Cooley DM, et al. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate. 2000;45(2):173–183.
-
4.
Leroy BE, Northrup N. Prostate cancer in dogs: comparative and clinical aspects. Vet J. 2009;180(2):149–162.
-
5.
Basinger RR, Rawlings CA, Barsanti JA, Oliver JE Jr, Crowell WA. Urodynamic alterations after prostatectomy in dogs without clinical prostatic disease. Vet Surg. 1987;16(6):405–410.
-
6.
Hardie EM, Stone EA, Spaulding KA, Cullen JM. Subtotal canine prostatectomy with the neodymium: yttrium-aluminum-garnet laser. Vet Surg. 1990;19(5):348–355.
-
7.
L'Eplattenier HF, van Nimwegen SA, van Sluijs FJ, Kirpensteijn J. Partial prostatectomy using Nd:YAG laser for management of canine prostate carcinoma. Vet Surg. 2006;35(4):406–411.
-
8.
Bennett TC, Matz BM, Henderson RA, et al. Total prostatectomy as a treatment for prostatic carcinoma in 25 dogs. Vet Surg. 2018;47(3):367–377.
-
9.
Basinger RR, Rawlings CA, Barsanti JA, Oliver JE Jr, Crowell WA. Urodynamic alterations associated with clinical prostatic diseases and prostatic surgery in 23 dogs. J Am Anim Hosp Assoc. 1989;25(6):385–392.
-
10.
Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92(3):488–498.
-
11.
Nolan MW, Kogan L, Griffin LR, et al. Intensity-modulated and image-guided radiation therapy for treatment of genitourinary carcinomas in dogs. J Vet Intern Med. 2012;26(4):987–995.
-
12.
Ravicini S, Baines SJ, Taylor A, Amores-Fuster I, Mason SL, Treggiari E. Outcome and prognostic factors in medically treated canine prostatic carcinomas: a multi-institutional study. Vet Comp Oncol. 2018;16(4):450–458.
-
13.
Maclean D, Maher B, Modi S, et al. Prostate artery embolization: a new, minimally invasive treatment for lower urinary tract symptoms secondary to prostate enlargement. Ther Adv Urol. 2017;9(8):209–216.
-
14.
Petrillo M, Pesapane F, Fumarola EM, et al. State of the art of prostatic arterial embolization for benign prostatic hyperplasia. Gland Surg. 2018;7(2):188–199.
-
15.
Salem R, Hairston J, Hohlastos E, et al. Prostate artery embolization for lower urinary tract symptoms secondary to benign prostatic hyperplasia: results from a prospective FDA-approved investigational device exemption study. Urology. 2018;120:205–210.
-
16.
Teichgräber U, Aschenbach R, Diamantis I, von Rundstedt F-C, Grim M-O, Franiel T. Prostate artery embolization: indication, technique and clinical results [in German]. Rofo. 2018;190(9):847–855.
-
17.
Sun F, Sánchez FM, Crisóstomo V, et al. Transarterial prostatic embolization: initial experience in a canine model. AJR Am J Roentgenol. 2011;197(2):495–501.
-
18.
Follette CM, Giuffrida MA, Balsa IM, et al. A systematic review of criteria used to report complications in soft tissue and oncologic surgical clinical research studies in dogs and cats. Vet Surg. 2020;49(1):61–69.
-
19.
Rosenthal R, Hoffmann H, Clavien PA, Bucher HC, Dell-Kuster S. Definition and classification of intraoperative complications (CLASSIC): Delphi study and pilot evaluation. World J Surg. 2015;39(7):1663–1671.
-
20.
Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969–977.
-
21.
Lee EW, Khan S. Recent advances in transarterial embolo-therapies in the treatment of hepatocellular carcinoma. Clin Mol Hepatol. 2017;23(4):265–272.
-
22.
Duffis EJ, Gandhi CD, Prestigiacomo CJ, et al. Head, neck, and brain tumor embolization guidelines. J Neurointerv Surg. 2012;4(4):251–255.
-
23.
Chiras J, Shotar E, Cormier E, Clarençon F, et al. Interventional radiology in bone metastases. Eur J Cancer Care (Engl). 2017;26(6). doi:10.1111/ecc.12741
-
24.
Gunn AJ, Patel AR, Rais-Bahrami S. Role of angio-embolization for renal cell carcinoma. Curr Urol Rep. 2018;19(10):76.
-
25.
He SH, Xu W, Sun ZW, et al. Selective arterial embolization for the treatment of sacral and pelvic giant cell tumor: a systematic review. Orthop Surg. 2017;9(2):139–144.
-
26.
Culp SH. Prostatic artery chemoembolization—a viable management option for men diagnosed with prostate cancer? J Vasc Interv Radiol. 2018;29(3):306.
-
27.
Mordasini L, Hechelhammer L, Diener PA, et al. Prostatic artery embolization in the treatment of localized prostate cancer: a bicentric prospective proof-of-concept study of 12 patients. J Vasc Interv Radiol. 2018;29(5):589–597.
-
28.
Pisco J, Bilhim T, Costa NV, Pinto Ribeiro M, Fernandes L, Oliveira AG. Safety and efficacy of prostatic artery chemoembolization for prostate cancer-initial experience. J Vasc Interv Radiol. 2018;29(3):298–305.
-
29.
Li Q, Duan F, Wang MQ, Zhang G-D, Yuan K. Prostatic arterial embolization with small sized particles for the treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia: preliminary results. Chin Med J (Engl). 2015;128(15):2072–2077.
-
30.
Wang M, Guo L, Duan F, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates. BJU Int. 2016;117(1):155–164.
-
31.
Liu L, Wang W, Chen H, et al. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma. Clin Cancer Res. 2014;20(6):1623–1631.
-
32.
Bargellini I, Bozzi E, Campani D, et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82(5):e212–e218.
-
33.
Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616–623.
-
34.
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
-
35.
Antunes AA, Carnevale FC, da Motta Leal Filho JM, et al. Clinical, laboratory, and urodynamic findings of prostatic artery embolization for the treatment of urinary retention related to benign prostatic hyperplasia. A prospective single-center pilot study. Cardiovasc Intervent Radiol. 2013;36(4):978–986.
-
36.
Palmieri C, Lean FZ, Akter SH, Romussi S, Grieco V. A retrospective analysis of 111 canine prostatic samples: histopathological findings and classification. Res Vet Sci. 2014;97(3):568–573.
-
37.
Bhatia S, Sinha VK, Kava BR, et al. Efficacy of prostatic artery embolization for catheter-dependent patients with large prostate sizes and high comorbidity scores. J Vasc Interv Radiol. 2018;29(1):78.e.12–84.e12. doi:10.1053/j.gastro.2019.08.027
-
38.
Culp WTN, Weisse C, Berent AC, et al. Early tumor response to intraarterial or intravenous administration of carboplatin to treat naturally occurring lower urinary tract carcinoma in dogs. J Vet Intern Med. 2015;29(3):900–907.
-
39.
Moss G. The adequacy of the cerebral collateral circulation: tolerance of awake experimental animals to acute bilateral common carotid artery occlusion. J Surg Res. 1974;16(4):337–338.
-
40.
Clendenin MA, Conrad MC. Collateral vessel development, following unilateral chronic carotid occlusion in the dog. Am J Vet Res. 1979;40(1):84–88.
-
41.
Clendenin MA, Conrad MC. Collateral vessel development after chronic bilateral common carotid artery occlusion in the dog. Am J Vet Res. 1979;40(9):1244–1248.
Advertisement
Procedural description and prospective evaluation of short-term outcome for the use of prostatic artery embolization in dogs with carcinoma of the prostate
Abstract
OBJECTIVE
To describe the procedure of prostatic artery embolization (PAE) in dogs with prostatic carcinoma and to evaluate the short-term outcome for treated dogs.
ANIMALS
20 client-owned dogs with prostatic carcinomas between May 2014 and July 2017.
PROCEDURES
In this prospective cohort study, dogs with carcinoma of the prostate underwent PAE with fluoroscopic guidance. Before and after PAE, dogs underwent CT and ultrasonographic examinations of the prostate, and each owner completed a questionnaire about the dog's clinical signs. Results for before versus after PAE were compared.
RESULTS
Prostatic artery embolization was successfully performed in all 20 dogs. Tenesmus, stranguria, and lethargy were significantly less common 30 days after PAE (n = 2, 1, and 0 dogs, respectively), compared with before PAE (9, 10, and 6 dogs, respectively). Median prostatic volume was significantly less 30 days after PAE (14.8 cm3; range, 0.4 to 48.1 cm3; interquartile [25th to 75th percentile] range, 6.7 to 19.5 cm3), compared with before PAE (21.7 cm3; range, 2.9 to 77.7 cm3; interquartile range, 11.0 to 35.1 cm3). All dogs had a reduction in prostatic volume after PAE, with a median prostatic volume loss of 39.4% (95% CI, 20.3% to 59.3%).
CONCLUSIONS AND CLINICAL RELEVANCE
Prostatic artery embolization was associated with decreased prostate volume and improved clinical signs in this cohort. The short-term response to PAE appears promising, and evaluation of the long-term impact on survival time is needed.
Contributor Notes
Powered by PubFactory